Mitochondrial Peroxiredoxin-3 protects against hyperglycemia induced myocardial damage in Diabetic cardiomyopathy

Free Radical Biology and Medicine

Volumn 97, Issue , 2016, Pages 489-500

  Arkat, Silpa ^a   Umbarkar, Prachi ^a   Singh, Sarojini ^a   Sitasawad, Sandhya L ^a  

^a UNIVERSITY OF PUNE   (India)

Author keywords

Apoptosis; Cardiac dysfunction; Diabetic cardiomyopathy; Oxidative stress; Peroxiredoxin 3

Indexed keywords

ANTIOXIDANT; BIOLOGICAL MARKER; GLUCOSE; INSULIN; MITOCHONDRIAL ENZYME; PEROXIREDOXIN 3; PEROXIREDOXIN 5; QUERCETIN; TRANSCRIPTION FACTOR NRF1; TRANSCRIPTION FACTOR NRF2; TROPONIN I; UNCOUPLING PROTEIN 3; REACTIVE OXYGEN METABOLITE; THIOREDOXIN REDUCTASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CELL DEATH; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DOWN REGULATION; GLUCOSE BLOOD LEVEL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE INJURY; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; LIPID PEROXIDATION; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATIVE PHOSPHORYLATION UNCOUPLING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; QRS INTERVAL; QTC INTERVAL; RAT; REDOX STRESS; UPREGULATION; ANIMAL; BLOOD; CELL LINE; ENZYME REPRESSION; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION; METABOLISM; PHYSIOLOGY; PROTECTION; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; BLOOD GLUCOSE; CELL LINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; ENZYME REPRESSION; GENE EXPRESSION; HYPERGLYCEMIA; MALE; OXIDATIVE STRESS; PEROXIREDOXIN III; PROTECTIVE FACTORS; QUERCETIN; RATS, WISTAR; REACTIVE OXYGEN SPECIES; THIOREDOXIN REDUCTASE 2;

EID: 84978915908     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2016.06.019     Document Type: Article

References (43)

1. [1] King, H., Aubert, R.E., Herman, W.H., Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 21 (1998), 1414–1431.
2. [2] Rubler, S., Sajadi, R.M., Araoye, M.A., Holford, F.D., Noninvasive estimation of myocardial performance in patients with diabetes. Effect of alcohol administration. Diabetes 27 (1978), 127–134.
3. [3] Rubler, S., Dlugash, J., Yuceoglu, Y.Z., Kumral, T., Branwood, A.W., Grishman, A., New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am. J. Cardiol. 30 (1972), 595–602.
4. [4] Devereux, R.B., Roman, M.J., Paranicas, M., O'Grady, M.J., Lee, E.T., Welty, T.K., et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101 (2000), 2271–2276.
5. [5] Singh, J.P., Larson, M.G., O'Donnell, C.J., Wilson, P.F., Tsuji, H., Lloyd-Jones, D.M., et al. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). Am. J. Cardiol. 86 (2000), 309–312.
6. [6] Francis, G.S., Diabetic cardiomyopathy: fact or fiction?. Heart 85 (2001), 247–248.
7. [7] Cai, L., Kang, Y.J., Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc. Toxicol. 1 (2001), 181–193.
8. [8] Feuerstein, G.Z., Young, P.R., Apoptosis in cardiac diseases: stress- and mitogen-activated signaling pathways. Cardiovasc. Res. 45 (2000), 560–569.
9. [9] Nishikawa, T., Edelstein, D., Du, X.L., Yamagishi, S., Matsumura, T., Kaneda, Y., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404 (2000), 787–790.
10. [10] Ide, T., Tsutsui, H., Kinugawa, S., Utsumi, H., Kang, D., Hattori, N., et al. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ. Res. 85 (1999), 357–363.
11. [11] Shen, X., Zheng, S., Metreveli, N.S., Epstein, P.N., Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 55 (2006), 798–805.
12. [12] Umbarkar, P., Singh, S., Arkat, S., Bodhankar, S.L., Lohidasan, S., Sitasawad, S.L., Monoamine oxidase-A is an important source of oxidative stress and promotes cardiac dysfunction, apoptosis, and fibrosis in diabetic cardiomyopathy. Free Radic. Biol. Med. 87 (2015), 263–273.
13. [13] Radi, R., Turrens, J.F., Chang, L.Y., Bush, K.M., Crapo, J.D., Freeman, B.A., Detection of catalase in rat heart mitochondria. J. Biol. Chem. 266 (1991), 22028–22034.
14. [14] Cadenas, E., Mitochondrial free radical production and cell signaling. Mol. Asp. Med. 25 (2004), 17–26.
15. [15] Cox, A.G., Winterbourn, C.C., Hampton, M.B., Mitochondrial peroxiredoxin involvement in antioxidant defence and redox signalling. Biochem. J. 425 (2010), 313–325.
16. [16] Watabe, S., Hiroi, T., Yamamoto, Y., Fujioka, Y., Hasegawa, H., Yago, N., et al. SP-22 is a thioredoxin-dependent peroxide reductase in mitochondria. Eur. J. Biochem. 249 (1997), 52–60.
17. [17] Chae, H.Z., Robison, K., Poole, L.B., Church, G., Storz, G., Rhee, S.G., Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc. Natl. Acad. Sci. USA 91 (1994), 7017–7021.
18. [18] Chae, H.Z., Kim, H.J., Kang, S.W., Rhee, S.G., Characterization of three isoforms of mammalian peroxiredoxin that reduce peroxides in the presence of thioredoxin. Diabetes Res. Clin. Pract. 45 (1999), 101–112.
19. [19] Rhee, S.G., Kang, S.W., Chang, T.S., Jeong, W., Kim, K., Peroxiredoxin, a novel family of peroxidases. IUBMB Life 52 (2001), 35–41.
20. [20] Cox, A.G., Peskin, A.V., Paton, L.N., Winterbourn, C.C., Hampton, M.B., Redox potential and peroxide reactivity of human peroxiredoxin 3. Biochemistry 48 (2009), 6495–6501.
21. [21] Matsushima, S., Ide, T., Yamato, M., Matsusaka, H., Hattori, F., Ikeuchi, M., et al. Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 113 (2006), 1779–1786.
22. [22] Lee, K.P., Shin, Y.J., Cho, S.C., Lee, S.M., Bahn, Y.J., Kim, J.Y., et al. Peroxiredoxin 3 has a crucial role in the contractile function of skeletal muscle by regulating mitochondrial homeostasis. Free Radic. Biol. Med. 77 (2014), 298–306.
23. [23] Banmeyer, I., Marchand, C., Clippe, A., Knoops, B., Human mitochondrial peroxiredoxin 5 protects from mitochondrial DNA damages induced by hydrogen peroxide. FEBS Lett. 579 (2005), 2327–2333.
24. [24] Yuan, J., Murrell, G.A., Trickett, A., Landtmeters, M., Knoops, B., Wang, M.X., Overexpression of antioxidant enzyme peroxiredoxin 5 protects human tendon cells against apoptosis and loss of cellular function during oxidative stress. Biochim. Biophys. Acta 1693 (2004), 37–45.
25. [25] Hu, Q.H., Wang, C., Li, J.M., Zhang, D.M., Kong, L.D., Allopurinol, rutin, and quercetin attenuate hyperuricemia and renal dysfunction in rats induced by fructose intake: renal organic ion transporter involvement. Am. J. Physiol. Ren. Physiol. 297 (2009), F1080–F1091.
26. [26] Kim, J.H., Kang, M.J., Choi, H.N., Jeong, S.M., Lee, Y.M., Kim, J.I., Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus. Nutr. Res. Pract. 5 (2011), 107–111.
27. [27] Bhutada, P., Mundhada, Y., Bansod, K., Bhutada, C., Tawari, S., Dixit, P., et al. Ameliorative effect of quercetin on memory dysfunction in streptozotocin-induced diabetic rats. Neurobiol. Learn. Mem. 94 (2010), 293–302.
28. [28] Fernandez-Twinn, D.S., Wayman, A., Ekizoglou, S., Martin, M.S., Hales, C.N., Ozanne, S.E., Maternal protein restriction leads to hyperinsulinemia and reduced insulin-signaling protein expression in 21-mo-old female rat offspring. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288 (2005), R368–R373.
29. [29] Zhang, Y., Babcock, S.A., Hu, N., Maris, J.R., Wang, H., Ren, J., Mitochondrial aldehyde dehydrogenase (ALDH2) protects against streptozotocin-induced diabetic cardiomyopathy: role of GSK3beta and mitochondrial function. BMC Med., 10, 2012, 40.
30. [30] Cai, L., Li, W., Wang, G., Guo, L., Jiang, Y., Kang, Y.J., Hyperglycemia-induced apoptosis in mouse myocardium: mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 51 (2002), 1938–1948.
31. [31] Boudina, S., Abel, E.D., Diabetic cardiomyopathy revisited. Circulation 115 (2007), 3213–3223.
32. [32] Miyamoto, N., Izumi, H., Miyamoto, R., Kondo, H., Tawara, A., Sasaguri, Y., et al. Quercetin induces the expression of peroxiredoxins 3 and 5 via the Nrf2/NRF1 transcription pathway. Investig. Ophthalmol. Vis. Sci. 52 (2011), 1055–1063.
33. [33] Basu, A., Haldar, S., The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol. Hum. Reprod. 4 (1998), 1099–1109.
34. [34] Yang, J., Liu, X., Bhalla, K., Kim, C.N., Ibrado, A.M., Cai, J., et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275 (1997), 1129–1132.
35. [35] Kalyanaraman, B., Darley-Usmar, V., Davies, K.J., Dennery, P.A., Forman, H.J., Grisham, M.B., et al. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free Radic. Biol. Med. 52 (2012), 1–6.
36. [36] Forman, H.J., Augusto, O., Brigelius-Flohe, R., Dennery, P.A., Kalyanaraman, B., Ischiropoulos, H., et al. Even free radicals should follow some rules: a guide to free radical research terminology and methodology. Free Radic. Biol. Med. 78 (2015), 233–235.
37. [37] Green, K., Brand, M.D., Murphy, M.P., Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 53:Suppl. 1 (2004), S110–S118.
38. [38] Hofmann, B., Hecht, H.J., Flohe, L., Peroxiredoxins. Biol. Chem. 383 (2002), 347–364.
39. [39] Rhee, S.G., Chae, H.Z., Kim, K., Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic. Biol. Med. 38 (2005), 1543–1552.
40. [40] Vivas-Mejia, P.E., Ozpolat, B., Chen, X., Lopez-Berestein, G., Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Int. J. Cancer 125 (2009), 264–275.
41. [41] Kim, S.H., Fountoulakis, M., Cairns, N., Lubec, G., Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. J. Neural Transm. Suppl., 2001, 223–235.
42. [42] Kim, S.H., Fountoulakis, M., Cairns, N., Lubec, G., Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. J. Neural Transm. Suppl., 2001, 223–235.
43. [43] Schroder, E., Eaton, P., Hydrogen peroxide as an endogenous mediator and exogenous tool in cardiovascular research: issues and considerations. Curr. Opin. Pharmacol. 8 (2008), 153–159.